INOVIO PHARMACEUTICALS, INC. CORAL SPRINGS, Florida, April 6, 2015 /PRNewswire/ --
The latest medical research and trials aimed to identify prevention of illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), Capnia, Inc. (NASDAQ: CAPN), Arena Pharmaceuticals, Inc., (NASDAQ: ARNA), Orexigen Therapeutics, Inc., (NASDAQ: OREX) & Inovio Pharmaceuticals, Inc., (NASDAQ: INO).
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope BioScience, Inc., its wholly-owned operating subsidiary, (the "Company") has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the Company's compound bryostatin-1 for the treatment of Alzheimer's disease. WCT is a leading worldwide clinical research organization with substantial experience in conducting a wide variety of clinical trials, including for treatment of Alzheimer's disease.
Neurotrope BioScience plans to submit its protocol to the FDA for this clinical trial in approximately 150 patients with moderately severe to severe Alzheimer's disease early in the second quarter of 2015. The Company expects to begin enrollment for the anticipated six month study sometime during the third quarter pending the FDA's approval of the protocol, and plans to enter into a definitive agreement with WCT for services related to the study at the appropriate time, subject to available resources.
Read the full NTRP press release at http://www.financialnewsmedia.com/profiles/ntrp.html
Neurotrope BioScience has an exclusive license to develop and commercialize bryostatin, a potent modulator of an enzyme called protein kinase C epsilon (PKCe) developed by the Blanchette Rockefeller Neurosciences Institute (BRNI). Based upon a number of BRNI pre-clinical and autopsy-validated human studies that have implicated PKCe deficits as a potential cause of Alzheimer's disease, the Company is approaching the treatment of the disease through the activation of PKCe. In animal models of Alzheimer's disease, activation of PKCe has been shown to improve learning and memory, induce synaptogenesis or growth of new synapses and prevent neurodegeneration. The Company has recently announced positive results of its Phase 2a safety study and is planning the larger proof of concept study mentioned above in moderately severe to severe Alzheimer's patients, which is intended to advance bryostatin for the treatment of this disease.
Additional developments - Severe Alzheimer's Patient Responds to Bryostatin Treatment - (published March 30, 2015) Researchers at the Blanchette Rockefeller Neurosciences Institute (BRNI) and the Marshall University Joan C. Edwards School of Medicine announced their findings from a new study entitled, "PSEN1 Variant in a Family with Atypical AD" http://iospress.metapress.com/content/g8k7712lm7456552/fulltext.pdf An Alzheimer's patient with very severe disease ("patient IV-18"), genetically confirmed to have a known variant of PSEN1, showed promising benefits during compassionate use treatment with the drug bryostatin 1. The drug was administered by intravenous infusion once a week for the first three weeks of each month. Within two weeks of the initiation of treatment, patient IV-18 showed clinical improvements that included word vocalization, directed attentional focus, restoration of swallowing, increased responses to verbal commands, and some improvement of range of limb motion. These improvements persisted for approximately eight weeks, despite an episode of severe pneumonia that required intubation and hospitalization for four weeks. According to BRNI, genetically confirmed Alzheimer's patients as severely advanced as patient IV-18 have not shown this level of clinical improvement previously with other treatment(s).
"We are very encouraged by the clinical improvements observed in patient IV-18. Nevertheless, controlled clinical trials are necessary to demonstrate safety and efficacy. BRNI believes, however, that this patient's response is supportive evidence that activation of Protein Kinase C (PKC) by potent activators such as Bryostatin, with both pre-clinical synaptogenic and anti-amyloid efficacies, could be a viable therapeutic approach for the treatment of severe Alzheimer disease", said Dr. Daniel Alkon, Scientific Director of BRNI and Chief Scientific Officer of Neurotrope BioScience, Inc. Read the full article at http://finance.yahoo.com/news/severe-alzheimers-patient-responds-bryostatin-172000986.html
In a market wrap of biotech performers from late last week: Capnia, Inc. (NASDAQ: CAPN) had the attention of investors on Thursday (4/2/15) closing up over 6% at $7.45 on over 2 Million Shares traded by market close. CAPN develops diagnostics and therapeutics based on its proprietary technology for precision metering of gas flow primarily in the United States. The company offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to the degradation of red blood cells. It also develops Serenz, a therapeutic product candidate that has completed phase II clinical trials for the treatment of symptoms related to allergic rhinitis.
Arena Pharmaceuticals, Inc., (NASDAQ: ARNA) closed up slightly on Thursday as well at $4.46 on just over 3.6Million shares traded by market close. ARNA, a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, including potentially pulmonary arterial hypertension that is in Phase II clinical trials.
Orexigen Therapeutics, Inc., (NASDAQ: OREX) a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical. OREX recently announced that the European Commission has granted marketing authorization for Mysimba(TM) (naltrexone HCl / bupropion HCl prolonged release) as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (greater than or equal to18 years) with an initial Body Mass Index (BMI) of greater than or equal to 30 kg/m2 (obese), or greater than or equal to 27 kg/m2 to 2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). This authorization applies to all 28 European Union (EU) member states.
Inovio Pharmaceuticals, Inc., (NASDAQ: INO) closed up over 2% at $8.69 on over 750,000 shares traded by the market close. INO, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company's SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/ [http://www.financialnewsmedia.com ]. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated two thousand dollars for news coverage of the current press release issued by Neurotrope, Inc. by a non-affiliated third party. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.comSOURCE FN Media Group, LLC
